Yahoo
    Toronto - Delayed Quote CAD

    Cardiol Therapeutics Inc. (CRDL.TO)

    1.4700 -0.1500 (-9.26%)
    At close: November 2 at 4:00:00 PM EST
    Loading Chart for CRDL.TO
    Chart Range Bar
    Interval:
    In partnership with ChartIQ

    Recent News

    Cardiol Therapeutics to Participate in Fireside Chat at B. Riley Securities Mind, Muscle & Vision Summit

    Cardiol Therapeutics to Participate in Fireside Chat at B. Riley Securities Mind, Muscle & Vision Summit
    CNW Group 3mo ago
    Cardiol Therapeutics Reports Results of 2026 Annual General Meeting of Shareholders

    Cardiol Therapeutics Reports Results of 2026 Annual General Meeting of Shareholders
    CNW Group 4mo ago
    Here's Why We're Watching Cardiol Therapeutics' (TSE:CRDL) Cash Burn Situation

    Here's Why We're Watching Cardiol Therapeutics' (TSE:CRDL) Cash Burn Situation
    Simply Wall St. 5mo ago
    Cardiol Therapeutics to Participate in Fireside Chat at H.C. Wainwright 4th Annual BioConnect Investor Conference at the NASDAQ

    Cardiol Therapeutics to Participate in Fireside Chat at H.C. Wainwright 4th Annual BioConnect Investor Conference at the NASDAQ
    CNW Group 5mo ago
    Cardiol Therapeutics Up In US Premarket As Expands Phase 3 Maveric Trial to Include 7 More Clinical Centers in the U.S.

    Cardiol Therapeutics Up In US Premarket As Expands Phase 3 Maveric Trial to Include 7 More Clinical Centers in the U.S.
    PREMIUM
    MT Newswires 6mo ago
    Cardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address Growing Interest in the Pivotal Program

    Cardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address Growing Interest in the Pivotal Program
    CNW Group 6mo ago
    Cardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address Growing Interest in the Pivotal Program

    Cardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address Growing Interest in the Pivotal Program
    PR Newswire 6mo ago
    Cardiol Therapeutics CEO: Phase III MAVERIC Nears Full Enrollment as CardiolRx Shows Myocarditis Promise

    Cardiol Therapeutics CEO: Phase III MAVERIC Nears Full Enrollment as CardiolRx Shows Myocarditis Promise
    MarketBeat 6mo ago
    Cardiol Therapeutics to Highlight MAVERIC Phase III Trial and Recently Published ARCHER Results in Live Interview with Barchart

    Cardiol Therapeutics to Highlight MAVERIC Phase III Trial and Recently Published ARCHER Results in Live Interview with Barchart
    TMX Newsfile 6mo ago
    Cardiol Therapeutics Fiscal 2025 Loss Narrows; Says Now Fully Funded Through Completion of MAVERIC trial

    Cardiol Therapeutics Fiscal 2025 Loss Narrows; Says Now Fully Funded Through Completion of MAVERIC trial
    PREMIUM
    MT Newswires 6mo ago
    Cardiol Therapeutics Announces Year-End 2025 Update on Operations

    Cardiol Therapeutics Announces Year-End 2025 Update on Operations
    TMX Newsfile 6mo ago

    Related Tickers

    Mobilize your Website
    View Site in Mobile | Classic
    Share by: